目的:分析肾移植术后不同基线血他克莫司谷浓度(Cn 0)的受者，将他克莫司普通剂型转换为他克莫司缓释胶囊后Cn 0的变化情况及效果。n 方法:根据肾移植受者术后基线Cn 0，将130例受者分为两组，A组受者转换前基线Cn 0≥6 μg/L，普通剂型与缓释剂型他克莫司剂量按1∶1转换，B组受者基线Cn 0<6 μg/L，普通剂型与缓释剂型他克莫司剂量按1∶1.1转换。比较两组在药物转换前后Cn 0的变化情况及相关肾脏指标的变化。n 结果:与转换前相比，转换后两组间他克莫司日平均用量和单位体重平均用量的差异均有统计学意义(n P<0.001)。与转换前相比，两组受者在转换后第7天的Cn 0明显降低，差异均有统计学意义(n P<0.001)。转换4周(第28天)时B组受者Cn 0波动范围较小，与转换前比较，差异无统计学意义(n P＝0.126)；而未调整初始剂量的A组受者转换第28天的Cn 0仍明显下降，与转换前比较，差异统计学意义(n P6 ng/ml and the conversion ratio between sustained-release and ordinary dosage forms was 1: 1. At a baseline C n 0 of <6 μg/L in group B, conversion dose should be raised appropriately. The changes of C n 0 after drug conversion and the effects of related renal parameters were compared between two groups.n Results:The daily average dosage of tacrolimus and the average dosage of unit weight per recipient pre-and post-conversion were significantly different between two groups (n P6 μg/L). Yet significant statistical difference in Cn 0 existed between Day 28 and pre-conversion (n P<0.001).n Conclusions:At a steady-state value of Cn 0 <6 μg/L in Chinese renal transplant population, dosage should be boosted by 10%-20%. This adjustment maintains the stability of blood concentration and avoids a large fluctuation of C n 0.n